bullish
Bukwang Pharmaceutical (003000 KS): Open Innovation Approach on Track to Launch New Drugs
466 Views03 Jun 2022 10:00
SUMMARY
- Bukwang Pharmaceutical (003000 KS) is developing innovative new drug candidates in partnership with pharmaceutical and bio-venture companies in Korea and abroad.
- Antipsychotic lurasidone (brand name: Latuda), in-licensed from Sumitomo Pharma is the lead candidate of Bukwang’s innovative drug pipeline. Lurasidone will be launched in 3–4 years in Korea.
- Recently, Bukwang announced positive phase 1 trial for SOL-804 for the treatment of prostate cancer, in-licensed from Solural Pharma. SOL-804 has an addressable market opportunity of KRW23 trillion in 2027.
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »Loading
Top Unpaywalled Insights
More »Loading
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Bukwang Pharm Announces A Capital Raise of 100 Billion Won28 Mar 2025
- Bukwang Pharmaceutical (003000 KS): High R&D Cost Put Pressure on Profit; Pain to Continue in Future12 Mar 2023
- Bukwang Pharmaceutical (003000 KS): Open Innovation Approach on Track to Launch New Drugs03 Jun 2022
x